NCT04116710View on ClinicalTrials.gov

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

August 12, 2021

Study Completion Date

April 1, 2022

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

HS-110 (viagenpumatucel-L)

Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig

BIOLOGICAL

HS-130

Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig

Trial Locations (1)

97213

Providence Portland Medical Center, Portland

Sponsors

Lead Sponsor

Heat Biologics
All Listed Sponsors
lead

Heat Biologics

INDUSTRY